JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Impact of IMP3 Expression on Chemotherapy Response and Prognosis in Triple-Negative Breast Cancer: A Retrospective Cohort Study

  • 0Department of Breast Surgery and Oncology, Nippon Medical School Tama Nagayama Hospital.
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi +

|

March 9, 2025

|

March 9, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in triple-negative breast cancer (TNBC) did not predict response to neoadjuvant chemotherapy (NAC). NAC effectiveness, not IMP3 status, is key for pathological complete response (pCR) in TNBC patients.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genetics

Background

  • Triple-negative breast cancer (TNBC) has a poor prognosis despite advances in neoadjuvant chemotherapy (NAC).
  • Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been linked to chemotherapy resistance and poor outcomes in TNBC.
  • The role of IMP3 in TNBC response to NAC requires further investigation.

Purpose Of The Study

  • To evaluate the association between IMP3 expression and NAC sensitivity in TNBC patients.
  • To assess the impact of IMP3 status on treatment outcomes, including pathological complete response (pCR) and disease-free survival (DFS).

Main Methods

  • IMP3 expression was assessed in tumor samples from 40 female TNBC patients.
  • Correlation between IMP3 positivity and clinical parameters, NAC response, and DFS was analyzed.
  • Ki-67 labeling index was used as an indicator of malignancy.

Main Results

  • IMP3-positive TNBC was observed in 27.5% of patients and was associated with a higher Ki-67 index, suggesting increased malignancy.
  • No significant correlation was found between IMP3 positivity and NAC resistance or DFS.
  • Patients achieved pCR irrespective of IMP3 status when treated with effective immunotherapy or high-dose chemotherapy.

Conclusions

  • NAC regimen is more critical for achieving pCR than IMP3 status in TNBC.
  • IMP3 may not be a definitive predictive marker for NAC response in TNBC, although it might indicate a poorer prognosis.
  • Further research is needed to elucidate the complex role of IMP3 in cancer stem cells (CSCs) and its implications in TNBC treatment.

Keywords: